A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.
about
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapyA polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteinsPrognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma.New advances in DPYD genotype and risk of severe toxicity under capecitabine.Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic studyTherapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.A predictive factor for the response to S-1 plus cisplatin in gastric cancer.Data-driven assessment of the association of polymorphisms in 5-Fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity.Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines.Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyThe effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysisNovel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.Genetic factors influencing pyrimidine-antagonist chemotherapy.Characterization of dihydropyrimidine dehydrogenase in human colorectal tumoursImmunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancerEvaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFTThe effect of surgically induced ischaemia on gene expression in a colorectal cancer xenograft model.Clinical application of biological markers for treatments of resectable non-small-cell lung cancers.A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracilBcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatmentThe role of molecular markers in predicting response to therapy in patients with colorectal cancer.Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray.Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase.Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells.Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells.Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivityExpression profiling of nucleotide metabolism-related genes in human breast cancer cells after treatment with 5-fluorouracil.
P2860
Q26851060-B6859EAD-1CC8-4B8A-AC54-E88BC8D6F49BQ28352447-1FB23CED-A96E-4177-BAF2-36BE4BC83BC3Q28369128-547218E0-FB40-4871-BD6F-706A0E19D839Q31098180-90977276-50F2-42A5-BF05-72342E30AC2EQ33648195-852B7DD4-EBDA-4B4A-9F5A-2C062019D3E0Q33682949-027BCC80-A39D-44C7-B446-0F53861529A6Q33884698-3926F926-914D-463D-8952-E32D70262B4EQ34074974-EC6223FC-D1C7-454C-BDF2-CE1213392E82Q34099389-AE6B910E-368C-4D1B-8B2A-FAB0A2F15E30Q34155072-6E0F2303-2F2A-4ABC-90A3-C814C97E6806Q34208097-8A5AF474-6307-4DB4-8FA3-7FED29F3E6A5Q34522413-BCFC2248-8A7B-43F4-B03A-A6F2DC3CF657Q34604303-5F264FB5-3C5A-420C-8290-C444287E82D4Q34606481-A3F87B7E-3044-451A-8DBD-76616905D866Q34658293-1B77413C-B8E9-4C61-B542-5023E7BF0F21Q34761260-BFD25800-6A48-4410-B893-E43CCF377533Q34775315-9F0E52C4-400A-4519-AF62-751535DB3E11Q35202502-B1E1DB81-06F9-494E-BB3A-5C4AB457D306Q35541901-21200960-912A-448F-BD88-AE3A4BA24016Q36057115-4A5AE7E5-2076-4A94-8533-0F601709F582Q36116454-C62F9EBB-7737-43F9-B17E-74C0A4BBC303Q36205831-B71B4A19-3D6B-41FF-AD5D-C4649D116CE4Q36295138-F93A65D1-0B26-4107-A862-3A0C5E05994DQ36609741-13103432-A06B-490D-97FF-E9BD67055C13Q36612324-D695A0FB-68B5-4E99-9272-073343E8EA37Q36613531-24360A27-E264-484C-8243-F4769DAE27CCQ36616611-53FA11DD-5876-4AE1-A5FE-ADD3296B1FCFQ36619294-19DECE41-4A99-461A-AB14-A31303A57094Q36691968-158E2E60-1304-4288-9D78-55F10DA396BEQ36992444-31B23E70-45F5-426B-84CD-FEBE0A0786E5Q37142001-8634AFC3-D573-4C50-805C-5F8C17C39A1CQ38165880-C60334DC-09DC-4010-ADFA-9BC04E1FA37AQ38353308-6B0DC627-8D51-4230-96A1-933E8818A57EQ38796384-6C88DDE6-B071-4C17-BF93-AB886FF35BE4Q38957071-C837AF2D-5D36-45A6-9560-9D0743ADA728Q39180988-0501E90E-14BA-43DA-982B-20FBBA43D5B9Q39245263-34C0FE84-B111-41DA-8256-591721BEF06DQ39544715-691F4A79-563E-450E-9B4C-781F21197FADQ39705491-6CBA99D3-F8AF-4E80-BC06-EFEF9DF6F156Q39883539-8254C946-6134-4A2D-88E8-B3F633EDCE75
P2860
A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
A role for dihydropyrimidine d ...... r sensitivity to fluorouracil.
@en
type
label
A role for dihydropyrimidine d ...... r sensitivity to fluorouracil.
@en
prefLabel
A role for dihydropyrimidine d ...... r sensitivity to fluorouracil.
@en
P2093
P1476
A role for dihydropyrimidine d ...... r sensitivity to fluorouracil.
@en
P2093
Chéradame S
Etienne MC
Fischel JL
Formento P
P304
P356
10.1016/0959-8049(94)00216-R
P577
1994-01-01T00:00:00Z